Editas Medicine
CompanyUnited States
Editas Medicine develops one asset, in phase 1 (EDIT-401 in hyperlipidemia). Mostly gene editing acting on lipid and ceramide metabolism; based in the United States.
- 1
- Asset
- Furthest stage
- Phase 1
- 0
- Trials
- 0
- Signals
Pipeline
1In vivo gene editing to lower LDL cholesterol levels
Phase 1, Gene editing, Lipid and ceramide metabolism, hyperlipidemia
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms1
- Similar companies6